27% profit every 20 days?
This is what Nic Chahine averages with his option buys. Not selling covered calls or spreads… BUYING options. Most traders don’t even have a winning percentage of 27% buying options. He has an 83% win rate. Here’s how he does it.
- Beam Therapeutics Inc (NASDAQ:BEAM) joins forces with Apellis Pharmaceuticals Inc (NASDAQ:APLS) to create new gene-editing treatments for complement-driven diseases.
- The partnership will leverage Beam’s base-editing technology to discover new treatments against various targets in the complement system.
- Under the five-year collaboration, Apellis will pay Beam $75 million cash, including $50 million upfront and $25 million one year down the line, along with unspecified milestones in exchange for preclinical work on six different programs.
- The programs will aim to complement protein C3 and other targets in the complement pathway to treat eye, liver, and brain diseases.
- Apellis will have exclusive rights to license each of the six programs and assume responsibility for subsequent development. However, Beam has the right to go 50-50 developing and commercializing one of them in the U.S.
- The deal comes days after Intellia Therapeutics Inc (NASDAQ:NTLA) unveiled first-in-human gene editing results showing that genes could be edited successfully inside the human body.
- The news sent shares of other gene-editing companies flying, including Beam.
- Apellis is developing its lead C3 inhibitor pegcetacoplan for several diseases, snagging its first FDA nod for paroxysmal nocturnal hemoglobinuria in May.
- Price Action: BEAM and APLS shares closed at $128.71 and $63.2 on Wednesday.
27% profit every 20 days?
This is what Nic Chahine averages with his option buys. Not selling covered calls or spreads… BUYING options. Most traders don’t even have a winning percentage of 27% buying options. He has an 83% win rate. Here’s how he does it.
ENTER TO WIN $500 IN STOCK OR CRYPTO
Enter your email and you'll also get Benzinga's ultimate morning update AND a free $30 gift card and more!